Seasonal pattern of manic episode admissions among bipolar I disorder patients is associated with male gender and presence of psychotic features.

J Affect Disord

Geha Mental Health Center, Petach-Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petach-Tikva, Israel.

Published: January 2016

Background: Bipolar I disorder (BD-I) patients demonstrate disrupted chronobiology expressed as seasonal variation in mood symptoms. The seasonal pattern (SP) specifier of mood disorders was recently extended by the DSM-5, to be applied to manic episodes. However, the significance of seasonality of manic episodes for the course of BD-I is unknown. In the present study we sought to identify clinical and demographic features that discriminate between BD-I patients with and without SP of manic admissions.

Methods: BD-I patients (n=148) admitted at least twice with the same mood exacerbation type, were retrospectively followed between 2005 and 2013. Demographic and clinical characteristics were compared between BD-I patients with or without SP of manic admissions.

Results: SP of manic episode admissions, found in 31 (26%) of 117 BD-I patients with repeated manic episode admissions, was associated with higher rates of male gender (p=0.01), presence of psychotic features (p=0.01) and comorbid substance use disorder (p<0.05) compared to patients without SP. In a multivariate analysis, SP of manic episode admissions was associated with the presence of psychotic features (OR 8.42, 95% CI: 1.05-67.65, p<0.05) and male gender (OR 3.23, 95% CI: 1.08-9.65, p<0.05), but not with comorbidity of substance use disorder (OR 1.79, 95% CI: 0.71-4.50, p=0.24).

Limitations: Seasonal psychological/environmental factors contributing to the emergent of mood episodes could not be ruled out.

Conclusions: Our results suggest that SP of manic admissions is associated with male gender and the presence of psychotic features, thus might be associated with more severe form of the disorder.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jad.2015.10.002DOI Listing

Publication Analysis

Top Keywords

bd-i patients
20
manic episode
12
episode admissions
12
seasonal pattern
8
bipolar disorder
8
male gender
8
presence psychotic
8
psychotic features
8
manic episodes
8
patients manic
8

Similar Publications

Objective: In recent years, there has been a rapid increase in reports upon social-cognition impairments in bipolar disorder. This study aimed to compare the characteristics of social cognition domains in bipolar I (BD I) and II (BD II) based on the findings to date.

Methods: A systematic literature search was conducted on Web of Science and PubMed from inception to 28 August 2024.

View Article and Find Full Text PDF

Background: There is lack of data on bipolar disorder (BD) type II from India.

Aim: To compare the demographic and clinical characteristics of patients with BD-I and BD-II using the data of the Bipolar Disorder Course and Outcome study from India (BiD-CoIN study).

Methodology: Using the data of the BiD-CoIN study, patients with BD-I and BD-II were compared for demographic and clinical variables.

View Article and Find Full Text PDF

The neural correlates of guilt highlight preclinical manifestations between bipolar and major depressive disorders.

Compr Psychiatry

December 2024

Department of Physical Medicine and Rehabilitation, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan; Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:

Background: Over 25 % of bipolar disorder (BD) patients are misdiagnosed with major depressive disorder (MDD). An urgent need exists for a biomarker to differentiate BD from MDD. Various manifestations and intensities of maladaptive guilt processing might uniquely contribute to the pathogenesis of BD compared to MDD.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the long-term safety, tolerability, and effect of olanzapine/samidorphan (OLZ/SAM) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder for up to 4 years, following the ENLIGHTEN clinical program.
  • - Out of 524 enrolled patients, the majority had schizophrenia, and common adverse effects included weight gain, headache, and anxiety, with minimal changes in metabolic parameters over the treatment duration.
  • - The treatment showed stable scores on the Clinical Global Impressions-Severity scale, indicating maintained symptom control and a long-term safety profile consistent with previous studies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!